Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Psychiatry

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Monoamine related functional gene variants and relationships to monoamine metabolite concentrations in CSF of healthy volunteers

  • Erik G Jönsson1Email author,
  • Jessica Bah2,
  • Jonas Melke2,
  • Rami Abou Jamra3,
  • Johannes Schumacher3,
  • Lars Westberg2,
  • Roland Ivo3,
  • Sven Cichon4,
  • Peter Propping3,
  • Markus M Nöthen4,
  • Elias Eriksson2 and
  • Göran C Sedvall1
BMC Psychiatry20044:4

https://doi.org/10.1186/1471-244X-4-4

Received: 19 September 2003

Accepted: 04 March 2004

Published: 04 March 2004

Abstract

Background

Concentrations of monoamine metabolites in human cerebrospinal fluid (CSF) have been used extensively as indirect estimates of monoamine turnover in the brain. CSF monoamine metabolite concentrations are partly determined by genetic influences.

Methods

We investigated possible relationships between DNA polymorphisms in the serotonin 2C receptor (HTR2C), the serotonin 3A receptor (HTR3A), the dopamine D4 receptor (DRD4), and the dopamine β-hydroxylase (DBH) genes and CSF concentrations of 5-hydroxyindolacetic acid (5-HIAA), homovanillic acid (HVA), and 3-methoxy-4-hydroxyphenylglycol (MHPG) in healthy volunteers (n = 90).

Results

The HTR3A 178 C/T variant was associated with 5-HIAA levels (p = 0.02). The DBH-1021 heterozygote genotype was associated with 5-HIAA (p = 0.0005) and HVA (p = 0.009) concentrations. Neither the HTR2C Cys23Ser variant, nor the DRD4 -521 C/T variant were significantly associated with any of the monoamine metabolites.

Conclusions

The present results suggest that the HTR3A and DBH genes may participate in the regulation of dopamine and serotonin turnover rates in the central nervous system.

Keywords

Serotonin receptor 2C geneserotonin receptor 3A genedopamine D4 receptor genedopamine β-hydroxylase genemonoamine metabolites (HVA5-HIAAMHPG)cerebrospinal fluid

Background

Concentrations of the major serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA), the major dopamine metabolite homovanillic acid (HVA), and the major norepinephrine metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG) in lumbar cerebrospinal fluid (CSF) have been used extensively as indirect measures of monoamine turnover in the brain of humans. Studies of human twins indicate that CSF 5-HIAA and HVA levels are under familial influence of both genetic and environmental origin, whereas MHPG is under major genetic influence [1]. In rhesus monkeys significant portions of CSF 5-HIAA, HVA, and MHPG in the central nervous system, have been shown to be determined by genetic mechanisms [2].

A number of serotonin receptors mediate the effects of serotonin. Among several functions, the serotonin receptor 5-HT2C, which is densely expressed throughout the brain [3], seems to be directly involved in the regulation of serotonin and norepinephrine activities in the brain [46]. The 5-HT2C gene (HTR2C) is localised to chromosome Xq24 [7]. An HTR2C variant giving rise to a Cystein to Serine substitution at position 23 of the protein has been identified [8]. This variant was shown to influence the CSF MHPG concentration in a Finnish sample of predominantly alcoholic offenders [9].

In contrast to all other serotonin receptors, which are G protein-coupled, the 5-HT3 receptor is a ligand-gated ion channel [10]. In the brain 5-HT3 receptors are localised in areas including the amygdala, hippocampus, and caudate nucleus. In addition to their effects on serotonin-regulated physiological processes, there are data suggesting that 5-HT3 receptors influence the activity of several other neurotransmitters, including norepinephrine and dopamine [1113]. The 5-HT3A gene (HTR3A) is localised to chromosome 11q23.1-q23.2 [10]. An HTR3A single nucleotide polymorphism (178 C/T) in the upstream regulatory region was recently discovered to be of putative functional importance, because luciferase reporter assays in human embryonal kidney cells showed a two to three times higher activity of the rare allele compared to the wildtype [14]. This HTR3A variant was reported to be associated with bipolar disorder [14] and the personality trait harm avoidance in women [15].

The dopamine D4 receptor has a predominantly cortical localisation in the human brain [16]. Among several effects, the dopamine D4 receptor seems to modulate dopamine synthesis and turnover [17, 18]. The dopamine D4 receptor gene (DRD4) is located to chromosome 11p15.5 [19]. Recently, a putative functional DRD4 upstream region variant (-521C/T) was discovered, where the -521C allele was reported to be 40% less active than -521T allele in a chloramphenicol acetyltransferase assay using human retinoblastoma cells [20]. This DRD4 variant was associated with schizophrenia [20] as well as the personality trait novelty seeking in some [2124] but not all studies [2531]. However, meta-analyses suggested association with both conditions [3234].

The enzyme dopamine β-hydroxylase (DβH) catalyses the conversion of dopamine to norepinephrine. DβH is localised in catecholamine-containing vesicles of noradrenergic and adrenergic cells [35, 36]. DβH enzyme activity has been shown to be heritable to a great extent [1, 37]. The DβH gene (DBH) is located on chromosome 9q34 [38]. Recently, a DBH promoter variant (-1021 C/T) was shown to strongly influence plasma DβH-activity [3941], indicating a functional effect. In the present study we have examined the HTR2C Cys23Ser, HTR3A 178 C/T, DRD4 -521 C/T and DBH -1021 C/T variants for possible relationships to concentrations of 5-HIAA, HVA, and MHPG in lumbar CSF from healthy Swedish volunteers.

Methods

Healthy human volunteers

The study was approved by the Ethics Committee of the Karolinska Hospital, Stockholm. Informed consent of the subjects was obtained after the nature of the procedures had been fully explained.

The characteristics and assessment of the subjects participating in the present study have been described previously [42, 43]. Caucasian individuals (n = 90) were recruited predominantly among students or hospital staff. Lumbar puncture (LP) was performed in all subjects. Height was also recorded. Back length, defined as the distance between the external occipital protuberance and the insertion point of the lumbar needle with the subject in the lying position, was measured in 63 subjects. Eight to 19 years later a structured interview was performed by a psychiatrist (EJ) to assess psychiatric morbidity (DSM-III-R; [44]), somatic illness and presence of mental and nervous system disorders among relatives. Subjects completed a questionnaire regarding smoking habits. Hospital records were obtained and examined for diagnosis. Genealogical data for antecedents up to the third degree were obtained from parish registers to assess the origin of the individuals. Subjects who reported any lifetime psychiatric disorder were excluded.

Of the 90 subjects 52 were men and 38 women. The age range at the time of the structured interview was 29 to 56, with a mean ± standard deviation of 40.5 ± 6.4 years. The mean age ± standard deviation at LP was 27.4 ± 5.9 years, age range 18 – 43. Thirty-six were university graduates. Twenty-one subjects had a family history of major mental illness defined as at least one first or second degree relative with schizophrenia, schizoaffective disorder, bipolar disorder, recurrent unipolar disorder, other non-organic psychosis, or who had committed suicide. Of the subjects 54 were or had been regular tobacco users, 25 were non-smokers or had only used tobacco once or a few times in their life, while data were missing for 11 individuals. Of the women, 15 used oral contraceptives at LP, 21 did not, while data were missing for two individuals. Except for oral contraceptives all participants were drug free at LP. Genealogical data implicated that 89.6% and 4.7% of the genes originated in ancestors born in Sweden and Finland, respectively, and the remaining 5.7% were distributed on 8 European countries.

CSF monoamine metabolite concentrations

All subjects had at least 8 h of bed-rest in the hospital, abstaining from food and smoking. CSF samples were obtained by LP between 8 and 9 a.m. with the subjects in the sitting (n = 41) or recumbent (n = 47) position. Samples of 12.5 ml CSF were drawn according to a standardised sampling procedure [45]. Samples were stored at below -20°C and analysed within two months. 5-HIAA, HVA, and MHPG concentrations were measured by mass fragmentography with deuterium labelled internal standards [46].

Genotype analyses

Venous blood was taken from all individuals into EDTA-containing tubes. DNA was isolated as previously described [47]. The HTR2C Cys23Ser variant was genotyped in accordance with Lappalainen et al [8]. The HTR3A 178 C/T, DRD4 -521 C/T, and DBH -1021 C/T variants were genotyped as previously described [15, 26, 48].

Data analyses

One way analysis of variance (ANOVA) was used for comparisons between genotypes and 5-HIAA, HVA, and MHPG concentrations, respectively. To correct monoamine metabolite levels for back length and use of oral contraceptives (among women), suggestive but discussed confounding variables for monoamine metabolite concentrations in lumbar CSF [42, 43, 49], analysis of covariance (ANCOVA) was used. For those subjects where back length was not available, estimated back length values, based on the relationship between back length and height, was used as previously described [42, 43]. Significance level was defined as a p-value lower than 0.05. Power was estimated in accordance with published methods [50, 51].

Results

Relationships between HTR2C genotypes and CSF monoamine metabolite concentrations

The HTR2C genotyping was successful in 86 individuals. Among men the allele frequencies were 0.88 (Cys23) and 0.12 (Ser23). In women the allele frequencies were 0.89 (Cys23) and 0.11 (Ser23), distributed on the following genotypes: Cys23Cys (81%), Cys23Ser (16%), and Ser23Ser (3%). As the HTR2C gene is localised on the X chromosome, each gender was analysed separately. Among women, the Ser23Ser and Cys23Ser genotypes were pooled and analysed versus the Cys23Cys genotype, because of the small number of Ser23Ser subjects. There were no significant relationship between genotypes and any of the CSF monoamine metabolite concentrations neither among men or women (table 1).
Table 1

Serotonin receptor 5-HT2C (HTR2C) genotypes and relationships to monoamine metabolite concentrations in human lumbar cerebrospinal fluid.

   

5-HIAA

HVA

MHPG

HTR2C Allele/genotype

Sex

n

Mean ± SD (nmol/L)

Fa pa

Fb pb

Mean ± SD (nmol/L)

Fa pa

Fb pb

Mean ± SD (nmol/L)

Fa pa

Fb pb

Cys23

Men

43

92 ± 40

F = 0.27

F = 0.13

166 ± 75

F = 0.73

F = 0.50

43 ± 8

F = 1.75

F = 1.48

Ser23

 

6

86 ± 16

p = 0.61

p = 0.72

144 ± 39

p = 0.40

p = 0.48

39 ± 4

p = 0.19

p = 0.23

Cys23Cys

Women

30

105 ± 39

F = 0.66

F = 0.57

194 ± 77

F = 2.14

F = 1.34

40 ± 6

F = 1.03

F = 0.91

Cys23Serc

 

6

118 ± 29

p = 0.42

p = 0.46d

231 ± 69

p = 0.15

p = 0.25e

44 ± 8

p = 0.32

p = 0.35f

Ser23Serc

 

1

107

  

229

  

38

  

5-HIAA = 5-hydroxyindoleacetic acid; HVA = homovanillic acid; MHPG = 3-methoxy-4-hydroxyphenylglycol. Statistical comparisons done on monoamine metabolite residuals correcteda and uncorrectedb for back length. c Cys23Ser and Ser23Ser genotypes were combined in the analyses. d Correction for use of oral contraceptives, F = 0.21, p = 0.65. e Correction for use of oral contraceptives, F = 0.84, p = 0.37. f Correction for use of oral contraceptives, F = 0.22, p = 0.64.

Relationships between HTR3A genotypes and CSF monoamine metabolite concentrations

The HTR3A 178 C/C genotype was the most frequent (67%), followed by the 178 C/T (30%) and the 178 T/T (3%) genotypes. The allele frequencies were 0.82 (178C) and 0.18 (178T). The 178 T/T and 178 C/T genotypes were pooled in the calculations, because of the small number of subjects carrying the 178 T/T genotype. In the total sample there were associations between the HTR3A variant and 5-HIAA (p = 0.002) and HVA (p = 0.006) concentrations, with higher concentrations of these monoamine metabolites in carriers of the T-containing genotypes (table 2). However, when corrected for back-length the association between the HTR3A variant and lumbar HVA concentrations was reduced to a trend (p = 0.08). In the male sub-sample, no significant relationships between HTR3A variation and 5-HIAA or HVA concentrations emerged. Among women the relationship between HTR3A variation and 5-HIAA concentrations, indicating higher 5-HIAA levels in subjects carrying the 178T allele, was significant both uncorrected (p = 0.004), corrected for back-length (p = 0.006), and corrected for use of oral contraceptives (p = 0.03; table 2). However, in the female sub-sample the association between HTR3A and HVA concentrations was of borderline significance (p = 0.05 uncorrected, p = 0.03 corrected for use of oral contraceptives), but was non-significant after correction for back-length (p = 0.12). Inspection of the CSF levels of the different genotype groups indicated a possible heterosis effect with regard to the CSF 5-HIAA and HVA concentrations [52]. We therefore also performed calculations pooling the homozygotic genotypes. However, the probability levels of significance did not exceed those obtained pooling the T/T and C/T genotypes (table 2). There were no significant relationships between the HTR3A genotype and MHPG concentrations (table 2).
Table 2

Serotonin receptor 5-HT3A (HTR3A) genotypes and relationships to monoamine metabolite concentrations in human lumbar cerebrospinal fluid.

   

5-HIAA

HVA

MHPG

HTR3A Genotype

Sex

n

Mean ± SD (nmol/L)

Fa pa

Fb pb

Mean ± SD (nmol/L)

Fa pa

Fb pb

Mean ± SD (nmol/L)

Fa pa

Fb pb

T/Tc

All

3

105 ± 52

F = 5.75

F = 10.22

203 ± 124

F = 3.25

F = 7.95

44 ± 5

F = 0.45

F = 0.29

C/Tc

 

27

117 ± 36

p = 0.02

p = 0.002

211 ± 67

p = 0.07

p = 0.006

43 ± 8

p = 0.50

p = 0.75

C/C

 

60

90 ± 35

  

166 ± 71

  

42 ± 7

  

T/Tc

Men

1

52

F = 0.31

F = 0.96

113

F = 0.75

F = 1.49

49

F = 0.20

F = 0.49

C/Tc

 

11

106 ± 33

p = 0.58

p = 0.33

193 ± 50

p = 0.39

p = 0.23

44 ± 9

p = 0.66

p = 0.49

C/C

 

40

90 ± 37

  

159 ± 11

  

43 ± 7

  

T/Tc

Women

2

131 ± 34

F = 8.55

F = 9.75

248 ± 137

F = 2.49

F = 4.05

41 ± 3

F = 0.68

F = 1.00

C/Tc

 

16

124 ± 37

p = 0.006

p = 0.004d

224 ± 76

p = 0.12

p = 0.05e

42 ± 7

p = 0.42

p = 0.32f

C/C

 

20

92 ± 30

  

179 ± 64

  

40 ± 6

  

5-HIAA = 5-hydroxyindoleacetic acid; HVA = homovanillic acid; MHPG = 3-methoxy-4-hydroxyphenylglycol. Statistical comparisons done on monoamine metabolite residuals correcteda and uncorrectedb for back length. c T/T and C/T genotypes were combined in the analyses. d Correction for use of oral contraceptives, F = 5.56, p = 0.02. e Correction for use of oral contraceptives, F = 1.76, p = 0.19. f Correction for use of oral contraceptives, F = 0.17, p = 0.68. Analysing heterosis, i.e. comparing homo- vs heterozygotes: All subjects 5-HIAA: F = 10.03, p = 0.002 (F = 5.71, p = 0.02 after correction for back length). All subjects HVA: F = 7.13, p = 0.009 (F = 2.28, p = 0.10). Men 5-HIAA: F = 1.96, p = 0.17 (F = 1.00, p = 0.32). Men HVA: 2.33, p = 0.13 (F = 1.40, p = 0.24). Women 5-HIAA: F = 6.73, p = 0.01 (F = 5.65, p = 0.02 and F = 3.76, p = 0.06 corrected for back length and use of oral contraceptives, respectively). Women HVA: F = 2.49, p = 0.12 (F = 1.03, p = 0.32 and F = 0.98, p = 0.33 corrected for back length and use of oral contraceptives, respectively).

Relationships between DRD4 genotypes and CSF monoamine metabolite concentrations

The DRD4 -521 C/T genotype was the most frequent (58%), followed by the -521 T/T (28%) and the -521 C/C genotypes (14%). The allele frequencies were 0.57 (-521T) and 0.43 (-521C). When women were analysed separately, the -521 C/C and -521 C/T genotypes were pooled, because of the small number of -521 C/C subjects. There was no significant relationship between DRD4 genotypes and any of the CSF monoamine metabolite concentrations neither in the total sample, nor among men or women (table 3).
Table 3

Dopamine D4 receptor (DRD4) genotypes and relationships to monoamine metabolite concentrations in human lumbar cerebrospinal fluid.

   

5-HIAA

HVA

MHPG

DRD4 Genotype

Sex

n

Mean ± SD (nmol/L)

Fa pa

Fb pb

Mean ± SD (nmol/L)

Fa pa

Fb pb

Mean ± SD (nmol/L)

Fa pa

Fb pb

C/C

All

13

104 ± 43

F = 0.76

F = 0.22

199 ± 94

F = 1.39

F = 0.52

42 ± 7

F = 2.62

F = 2.68

C/T

 

52

99 ± 34

p = 0.47

p = 0.80

176 ± 68

p = 0.25

p = 0.59

41 ± 7

p = 0.08

p = 0.07

T/T

 

25

96 ± 41

  

181 ± 77

  

45 ± 8

  

C/C

Men

12

104 ± 44

F = 0.99

F = 0.98

197 ± 98

F = 1.49

F = 1.60

43 ± 7

F = 1.93

F = 2.06

C/T

 

26

91 ± 35

p = 0.38

p = 0.38

156 ± 63

p = 0.24

p = 0.21

41 ± 8

p = 0.16

p = 0.14

T/T

 

14

84 ± 32

  

155 ± 50

  

46 ± 8

  

C/Cc

Women

1

107

F = 0.004

F = 0.11

229

F = 0.003

F = 0.48

38

F = 0.78

F = 1.23

C/Tc

 

26

106 ± 33

p = 0.95

p = 0.74d

195 ± 68

p = 0.96

p = 0.49e

40 ± 6

p = 0.38

p = 0.27f

T/T

 

11

111 ± 47

  

214 ± 93

  

43 ± 7

  

5-HIAA = 5-hydroxyindoleacetic acid; HVA = homovanillic acid; MHPG = 3-methoxy-4-hydroxyphenylglycol. Statistical comparisons done on monoamine metabolite residuals correcteda and uncorrectedb for back length. c C/C and C/T genotypes were combined in the analyses. d Correction for use of oral contraceptives, F = 0.38, p = 0.54. e Correction for use of oral contraceptives, F = 0.04, p = 0.84. f Correction for use of oral contraceptives, F = 1.09, p = 0.30.

Relationships between DBH genotypes and CSF monoamine metabolite concentrations

The DBH -1021 C/C genotype was the most frequent (71%), followed by the -1021 C/T (26%) and the -1021 T/T genotypes (3%). The allele frequencies were 0.84 (-1021C) and 0.16 (-1021T). The -1021 T/T and -1021 C/T genotypes were pooled in the calculations, because of the small number of subjects with the -1021 T/T genotype. In the total sample there was an association between DBH genotype and 5-HIAA concentrations (p = 0.01 uncorrected, p = 0.003 when corrected for back-length), with higher 5-HIAA levels in subjects with the -1021T containing genotypes (table 4). This relationship reached significance also among men (p = 0.06 uncorrected, p = 0.04 corrected for back length), but not among women (table 4). In the total sample there was a tendency for association (p = 0.09) between the DBH variant and HVA concentrations, with higher HVA levels in -1021T carriers (table 4). When corrected for back-length the strength of this difference was significant (p = 0.03). Neither in the smaller male or female sub-samples this difference reached significance (table 4).
Table 4

Dopamine β-hydroxylase (DBH) genotypes and relationships to monoamine metabolite concentrations in human lumbar cerebrospinal fluid.

   

5-HIAA

HVA

MHPG

DBH Genotype

Sex

n

Mean ± SD (nmol/L)

Fa pa

Fb pb

Mean ± SD (nmol/L)

Fa pa

Fb pb

Mean ± SD (nmol/L)

Fa pa

Fb pb

C/C

All

64

92 ± 35

F = 9.07

F = 6.42

172 ± 66

F = 5.21

F = 3.00

42 ± 7

F = 0.01

F = 0.01

C/Tc

 

23

118 ± 39

p = 0.003

p = 0.01

208 ± 93

p = 0.02

p = 0.09

42 ± 9

p = 0.90

p = 0.93

T/Tc

 

3

78 ± 25

  

151 ± 18

  

40 ± 5

  

C/C

Men

36

86 ± 36

F = 4.68

F = 3.80

156 ± 56

F = 2.22

F = 1.81

43 ± 7

F = 0.08

F = 0.04

C/Tc

 

15

107 ± 35

p = 0.04

p = 0.06

186 ± 98

p = 0.14

p = 0.18

43 ± 10

p = 0.78

p = 0.84

T/Tc

 

1

95

  

160

  

45

  

C/C

Women

28

101 ± 31

F = 4.08

F = 3.37

192 ± 73

F = 3.72

F = 1.79

41 ± 6

F = 0.03

F = 0.08

C/Tc

 

8

139 ± 38

p = 0.05

p = 0.07e

249 ± 72

p = 0.06

p = 0.19d

41 ± 7

p = 0.87

p = 0.78f

T/Tc

 

2

70 ± 30

  

147 ± 23

  

38 ± 4

  

5-HIAA = 5-hydroxyindoleacetic acid; HVA = homovanillic acid; MHPG = 3-methoxy-4-hydroxyphenylglycol. Statistical comparisons done on monoamine metabolite residuals correcteda and uncorrectedb for back length. c T/T and C/T genotypes were combined in the analyses. d Correction for use of oral contraceptives, F = 0.88, p = 0.36. e Correction for use of oral contraceptives, F = 0.46, p = 0.50. f Correction for use of oral contraceptives, F = 0.003, p = 0.96. Analysing heterosis, i.e. comparing homo- vs heterozygotes: All subjects 5-HIAA: F = 9.56, p = 0.003 (F = 13.07, p = 0.0005 after correction for back length). All subjects HVA: F = 4.43, p = 0.04 (F = 7.24, p = 0.009). Men 5-HIAA: F = 3.85, p = 0.06 (F = 4.6187, p = 0.04). Men HVA: 1.95, p = 0.17 (F = 2.31, p = 0.14). Women 5-HIAA: F = 9.14, p = 0.005 (F = 9.74, p = 0.004 and F = 4.11, p = 0.05 corrected for back length and use of oral contraceptives, respectively). Women HVA: F = 4.43, p = 0.04 (F = 6.42, p = 0.02 and F = 1.81, p = 0.19 corrected for back length and use of oral contraceptives, respectively).

We also performed calculations pooling the homozygotic genotypes, i.e. analysing possible heterosis [52]. In the total sample there was an association between DBH heterozygosity and 5-HIAA concentrations (p = 0.003 uncorrected, p = 0.0005 when corrected for back-length) (table 4). This relationship reached significance also among men (p = 0.06 uncorrected, p = 0.04 corrected for back length) and women (p = 0.005 uncorrected, p = 0.02 corrected for back length, p = 0.05 corrected for use of oral contraceptives; table 4). In the total sample there was an association (p = 0.04 uncorrected, p = 0.009 corrected for back-length) between DBH heterozygosity and HVA concentrations (table 4). This association failed to obtain significance in the smaller male sub-sample. Among women there was an association (p = 0.04 uncorrected, p = 0.02 corrected for back-length), which however did not survived correction for use of oral contraceptives (p = 0.18; table 4).

There were no significant relationships between the DBH genotype and MHPG concentrations (table 4).

Given α = 0.05 the present study had a power of 0.93 – 0.96 (total sample), 0.67 – 0.81 (men), or 0.53 – 0.67 (women) to detect differences of a large effect size (f = 0.40). For differences of a medium effect size (f = 0.25) the power was 0.54 – 0.65 (total sample) or less.

Discussion

The present study is, to our knowledge, the first to investigate three potentially functional candidate gene variants (HTR3A 178 C/T, DRD4 -521 C/T, DBH -1021 C/T) in the context of monoamine metabolite concentrations in cerebrospinal fluid from human healthy volunteers. Association was detected between two of these gene variants (HTR3A 178 C/T, DBH -1021 C/T) and the indirect measures of monoamine activity in the brain.

However, we were not able to replicate the previously reported finding of higher CSF MHPG concentrations in HTR2C Ser23 compared to Cys23 carriers among men [9]. On the contrary, our male sub-sample showed a non-significant relationship in the opposite direction, i.e. higher MHPG concentrations in Cys23 subjects (table 1). When we added another 23 men, excluded from the main analysis because of reported life-time psychiatric disorder, mostly alcohol abuse, depressive or anxiety disorders, this difference reached nominal significance (F = 4.44, d.f. = 71, p = 0.04), a result robust for correction for back-length (p = 0.04) and presence of life-time psychiatric disorder (p = 0.04), respectively (data not shown). Reasons for the different results in the two studies may include the different selection of subjects. The previous study included 73% alcoholic violent offenders and 27% healthy controls of Finnish ethnicity, and the HTR2C genotype effect was most prominent among the offenders [9], whereas the present study only included healthy subjects. The present study may lack power to detect the previous relationship. Alternatively, assuming different relationships between alcoholic violent offenders and healthy controls, the Finnish study may be under-powered concerning control subjects. It is also possible that both results are valid, but the results reflect an association to a linked variant, and that the degree of linkage between the HTR2C Cys23Ser variant and the 'real' functional polymorphism differs between the two populations investigated. There may also be a difference between the two populations with regard to other genes interacting with the present to influence MHPG concentrations. It is also possible that the Finnish, the present or both results have emerged by chance.

Subjects carrying the rarer HTR3A 178T allele, which has been associated with higher protein expression than the wild-type variant [14], displayed higher lumbar CSF 5-HIAA concentrations. This suggests that a more efficient variant of the 5-HT3 receptor, involved in the regulation of serotonin activities, enhances brain serotonin turnover, giving rise to higher levels of the serotonin degradation product in CSF.

We were not able to find any significant relationships between DRD4 -521 C/T variation and CSF monoamine metabolite concentrations. This is in accordance with previous studies, analysing a DRD4 exon 3 variable number of tandem repeat variant [42, 53]. In the present report there was a trend for an association between the DRD4 -521 C/T genotypes and CSF MHPG concentrations. This may mean that the present study does not have sufficient power to detect such a relationship, or that this trend reflects a tendency to a false positive finding. The results so far obtained suggest that the DRD4 gene does not have a large impact on the monoamine turnover in the brain as reflected by the major degradation products of these compounds in healthy human subjects.

One would expect that functional variants of the gene encoding the dopamine β-hydroxylase would primarily affect the catecholamines, in particular norepinephrine. However, in the present study the strongest relationship emerged between the DBH -1021 C/T variant and CSF 5-HIAA levels. Complex interactions between the noradrenergic and serotonergic systems have been reported [54, 55]. Altered noradrenergic activity may alter the firing activity of serotonergic neurons, leaving a possibility for a decreased or increased availability of norepinehprine to be involved in these interactions. One might speculate that a more effective DBH variant, giving rise to an enhanced norepinephrine formation, facilitates noradrenergic activity, which in its turn facilitates serotonergic activity, giving rise to larger amounts of the serotonin degradation product 5-HIAA. There was also an association between DBH -1021 C/T variation and the major dopamine degradation product, indicating higher HVA levels in subjects with a less effective enzyme variant. This is in accordance with the theory that a less effective conversion of dopamine to norepinephrine would lead to higher amounts of dopamine, and in turn to its degradation product HVA. However, the stronger associations between heterozygotic genotypes and 5-HIAA and HVA concentrations, examples of positive heterosis [52], rather indicate a more complex physiology including interactions based on hidden stratification of unknown factors or heterozygotic advantage [52]. In this context, an interaction with e.g. the monoamine oxidase A gene, where more effective variants have been reported to increase 5-HIAA concentrations [43, 56], may be a possibility. However, these latter results further complicate the task, as they call into question the use of monoamine metabolites as straightforward, although indirect, measures of brain turnover. This may mean that high levels of 5-HIAA may reflect a more effective degradation process rather than an enhanced overall turnover giving a possibility for reduced serotonin transmission to be associated with high levels of 5-HIAA.

It is possible that the present associations may have emerged by chance. Applying Bonferroni's correction would give a p-value of < 0.0011 (0.05/45) to be considered significant. Only one of the reported relationships, i.e. the association between DBH heterozygosity and CSF 5-HIAA levels, would survive such a correction procedure. On the other hand, although relatively large to constitute a sample of healthy subjects investigated by a demanding procedure, i.e. lumbar puncture, the present sample is small from a statistical point of view. The power of the present study was adequate to detect differences of large, but not medium to small effect sizes. Thus, it cannot be excluded that relationships of smaller magnitudes may have escaped our analysis attempts. Applying strict corrections for multiple testing would make investigations like the present impossible to perform, because a sample big enough to withstand such a correction procedure would probably never be possible to obtain. This is especially true taking the detection of small effects into account.

Conclusions

If replicated, the present results suggests that the HTR3A and DBH variants participate differentially in the regulation of serotonin turnover in the central nervous system of human subjects. It is also suggested that the DBH variant differentially influence dopamine turnover in the brain. The results give some support for an influence of the HTR2C variant on norepinephrine turnover in men, but do not favour a major differential influence of DRD4 gene activities on monoamine metabolite concentrations in lumbar CSF.

Declarations

Acknowledgements

This study was supported by grants from the Swedish Research Council (8668, K2004-21X-15078-01A), Deutsche Forschungsgemeinschaft (SFB400, TPA3), the Fund for Scientific Research – Flanders (G.0425.02), the National Institute for Mental Health (44814), Söderström-Königska Foundation, the Lundberg Foundation, the Wallenberg Foundation, and the HUBIN project. We thank Kjerstin Lind and Alexandra Tylec for technical assistance.

Authors’ Affiliations

(1)
Department of Clinical Neuroscience, Psychiatry Section, HUBIN project, Karolinska Institutet
(2)
Department of Pharmacology, Göteborg University
(3)
Institute of Human Genetics, University of Bonn
(4)
Department of Medical Genetics, University of Antwerp

References

  1. Oxenstierna G, Edman G, Iselius L, Oreland L, Ross SB, Sedvall G: Concentrations of monoamine metabolites in the cerebrospinal fluid of twins and unrelated individuals – a genetic study. J Psychiatr Res. 1986, 20: 19-29. 10.1016/0022-3956(86)90020-8.View ArticlePubMedGoogle Scholar
  2. Higley JD, Thompson WW, Champoux M, Goldman D, Hasert MF, Kraemer GW, Scanlan JM, Suomi SJ, Linnoila M: Paternal and maternal genetic and environmental contributions to cerebrospinal fluid monoamine metabolites in rhesus monkeys (Macaca mulatta). Arch Gen Psychiatry. 1993, 50: 615-623.View ArticlePubMedGoogle Scholar
  3. Pompeiano M, Palacios JM, Mengod G: Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors. Brain Res Mol Brain Res. 1994, 23: 163-178. 10.1016/0169-328X(94)90223-2.View ArticlePubMedGoogle Scholar
  4. Blandina P, Goldfarb J, Walcott J, Green JP: Serotonergic modulation of the release of endogenous norepinephrine from rat hypothalamic slices. J Pharmacol Exp Ther. 1991, 256: 341-347.PubMedGoogle Scholar
  5. Chiang G, Aston-Jones G: A 5-hydroxytryptamine2 agonist augments gamma-aminobutyric acid and amino acid inputs to noradrenergic locus coeruleus neurons. Neuroscience. 1993, 54: 409-420. 10.1016/0306-4522(93)90262-E.View ArticlePubMedGoogle Scholar
  6. Done CJ, Sharp T: Biochemical evidence for the regulation of central noradrenergic activity by 5-HT1A and 5-HT2 receptors: microdialysis studies in the awake and anaesthetized rat. Neuropharmacology. 1994, 33: 411-421. 10.1016/0028-3908(94)90071-X.View ArticlePubMedGoogle Scholar
  7. Milatovich A, Hsieh CL, Bonaminio G, Tecott L, Julius D, Francke U: Serotonin receptor 1c gene assigned to X chromosome in human (band q24) and mouse (bands D-F4). Hum Mol Genet. 1992, 1: 681-684.View ArticlePubMedGoogle Scholar
  8. Lappalainen J, Zhang L, Dean M, Oz M, Ozaki N, Yu DH, Virkkunen M, Weight F, Linnoila M, Goldman D: Identification, expression, and pharmacology of a Cys23-Ser23 substitution in the human 5-HT2c receptor gene (HTR2C). Genomics. 1995, 27: 274-279. 10.1006/geno.1995.1042.View ArticlePubMedGoogle Scholar
  9. Lappalainen J, Long JC, Virkkunen M, Ozaki N, Goldman D, Linnoila M: HTR2C Cys23Ser polymorphism in relation to CSF monoamine metabolite concentrations and DSM-III-R psychiatric diagnoses. Biol Psychiatry. 1999, 46: 821-826. 10.1016/S0006-3223(98)00361-8.View ArticlePubMedGoogle Scholar
  10. Miyake A, Mochizuki S, Takemoto Y, Akuzawa S: Molecular cloning of human 5-hydroxytryptamine3 receptor: heterogeneity in distribution and functionamong species. Mol Pharmacol. 1995, 48: 407-416.PubMedGoogle Scholar
  11. Matsumoto M, Yoshioka M, Togashi H, Tochihara M, Ikeda T, Saito H: Modulation of norepinephrine release by serotonergic receptors in the rat hippocampus as measured by in vivo microdialysis. J Pharmacol Exp Ther. 1995, 272: 1044-1051.PubMedGoogle Scholar
  12. Benloucif S, Keegan MJ, Galloway MP: Serotonin-facilitated dopamine release in vivo: pharmacological characterization. J Pharmacol Exp Ther. 1993, 265: 373-377.PubMedGoogle Scholar
  13. Tricklebank MD: The functional importance of 5-HT3 receptors in the interactions between serotonergic and dopaminergic systems in the CNS. In Central and Peripheral 5-HT3 receptors. Edited by: Hamen M. 1992, London: Academic Press, 189-205.Google Scholar
  14. Niesler B, Flohr T, Nöthen MM, Fischer C, Rietschel M, Franzek E, Albus M, Propping P, Rappold GA: Association between the 5' UTR variant C178T of the serotonin receptor gene HTR3A and bipolar affective disorder. Pharmacogenetics. 2001, 11: 471-475. 10.1097/00008571-200108000-00002.View ArticlePubMedGoogle Scholar
  15. Melke J, Westberg L, Nilsson S, Landén M, Soderstrom H, Baghaei F, Rosmond R, Holm G, Björntorp P, Nilsson LG, Adolfsson R, Eriksson E: A polymorphism in the serotonin receptor 3A gene (HTR3A) is associated with harm avoidance in women. Arch Gen Psychiatry. 2003, 60: 1017-1023. 10.1001/archpsyc.60.10.1017.View ArticlePubMedGoogle Scholar
  16. Lahti RA, Roberts RC, Conley RR, Cochrane EV, Mutin A, Tamminga CA: D2-type dopamine receptors in postmortem human brain sections from normal and schizophrenic subjects. Neuroreport. 1996, 7: 1945-1948.View ArticlePubMedGoogle Scholar
  17. Rubinstein M, Phillips TJ, Bunzow JR, Falzone TL, Dziewczapolski G, Zhang G, Fang Y, Larson JL, McDougall JA, Chester JA, Saez C, Pugsley TA, Gershanik O, Low MJ, Grandy DK: Mice lacking dopamine D4 receptors are supersensitive to ethanol, cocaine, and methamphetamine. Cell. 1997, 90: 991-1001.View ArticlePubMedGoogle Scholar
  18. Tarazi FI, Baldessarini RJ: Brain dopamine D(4) receptors: basic and clinical status. Int J Neuropsychopharmcol. 1999, 2: 41-58. 10.1017/S1461145799001352.View ArticleGoogle Scholar
  19. Gelernter J, Kennedy JL, Van Tol HHM, Civelli O, Kidd KK: The D4 dopamine receptor (DRD4) maps to distal 11p close to HRAS. Genomics. 1992, 13: 208-210.View ArticlePubMedGoogle Scholar
  20. Okuyama Y, Ishiguro H, Toru M, Arinami T: A genetic polymorphism in the promoter region of DRD4 associated with expression and schizophrenia. Biochem Biophys Res Commun. 1999, 258: 292-295. 10.1006/bbrc.1999.0630.View ArticlePubMedGoogle Scholar
  21. Okuyama Y, Ishiguro H, Nankai M, Shibuya H, Watanabe A, Arinami T: Identification of a polymorphism in the promoter region of DRD4 associated with the human novelty seeking personality trait. Mol Psychiatry. 2000, 5: 64-69. 10.1038/sj.mp.4000563.View ArticlePubMedGoogle Scholar
  22. Ronai Z, Szekely A, Nemoda Z, Lakatos K, Gervai J, Staub M, Sasvari-Szekely M: Association between Novelty Seeking and the -521 C/Tpolymorphism in the promoter region of the DRD4 gene. Mol Psychiatry. 2001, 6: 35-38. 10.1038/sj.mp.4000832.View ArticlePubMedGoogle Scholar
  23. Bookman EB, Taylor RE, Adams-Campbell L, Kittles RA: DRD4 promoter SNPs and gender effects on Extraversion in African Americans. Mol Psychiatry. 2002, 7: 786-789. 10.1038/sj.mp.4001075.View ArticlePubMedGoogle Scholar
  24. Lee HJ, Lee HS, Kim YK, Kim SH, Kim L, Lee MS, Joe SH, Jung IK, Suh KY, Kim S: Allelic variants interaction of dopamine receptor D4 polymorphism correlate with personality traits in young Korean female population. Am J Med Genet. 2003, 118B: 76-80. 10.1002/ajmg.b.10047.View ArticlePubMedGoogle Scholar
  25. Mitsuyasu H, Hirata N, Sakai Y, Shibata H, Takeda K, Ninomiya H, Kawasaki H, Tashiro N, Fukumaki Y: Association analysis of polymorphisms in the upstream region of the human dopamine D4 receptor gene (DRD4) with schizophrenia and personality traits. J Hum Genet. 2001, 46: 26-31. 10.1007/s100380170120.View ArticlePubMedGoogle Scholar
  26. Jönsson EG, Ivo R, Forslund K, Mattila-Evenden M, Rylander G, Cichon S, Propping P, Nöthen MM, Åsberg M, Sedvall GC: No association between a promoter dopamine D4 receptor gene variant and schizophrenia. Am J Med Genet. 2001, 105: 525-528. 10.1002/ajmg.1478.View ArticlePubMedGoogle Scholar
  27. Jönsson EG, Ivo R, Gustavsson JP, Geijer T, Forslund K, Mattila-Evenden M, Rylander G, Cichon S, Propping P, Bergman H, Åsberg M, Nöthen MM: No association between dopamine D4 receptor gene variants and Novelty Seeking. Mol Psychiatry. 2002, 7: 18-20. 10.1038/sj.mp.4001950.View ArticlePubMedGoogle Scholar
  28. Ekelund J, Suhonen J, Järvelin MR, Peltonen L, Lichtermann D: No association of the -521 C/T polymorphism in the promoter of DRD4 with novelty seeking. Mol Psychiatry. 2001, 6: 618-619. 10.1038/sj.mp.4000943.View ArticlePubMedGoogle Scholar
  29. Strobel A, Lesch KP, Hohenberger K, Jatzke S, Gutzeit HO, Anacker K, Brocke B: No association between dopamine D4 receptor gene exon III and-521C/T polymorphism and Novelty Seeking. Mol Psychiatry. 2002, 7: 537-538. 10.1038/sj.mp.4001027.View ArticlePubMedGoogle Scholar
  30. Strobel A, Spinath FM, Angleitner A, Riemann R, Lesch KP: Lack of association between polymorphisms of the dopamine D4 receptor gene and personality. Neuropsychobiology. 2003, 47: 52-56. 10.1159/000068876.View ArticlePubMedGoogle Scholar
  31. Joyce PR, Rogers GR, Miller AL, Mulder RT, Luty SE, Kennedy MA: Polymorphisms of DRD4 and DRD3 and risk of avoidant and obsessive personality traits and disorders. Psychiatry Res. 2003, 119: 1-10. 10.1016/S0165-1781(03)00124-0.View ArticlePubMedGoogle Scholar
  32. Schinka JA, Letsch EA, Crawford FC: DRD4 and novelty seeking: results of meta-analyses. Am J Med Genet. 2002, 114: 643-648. 10.1002/ajmg.10649.View ArticlePubMedGoogle Scholar
  33. Munafò MR, Clark TG, Moore LR, Payne E, Walton R, Flint J: Genetic polymorphisms and personality in healthy adults: a systematic review and meta-analysis. Mol Psychiatry. 2003, 8: 471-484. 10.1038/sj.mp.4001326.View ArticlePubMedGoogle Scholar
  34. Jönsson EG, Sedvall GC, Nöthen MM, Cichon S: Dopamine D4 receptor gene (DRD4) variants and schizophrenia: meta-analyses. Schizophr Res. 2003, 61: 111-119. 10.1016/S0920-9964(02)00287-6.View ArticlePubMedGoogle Scholar
  35. Kemper CM, O'Connor DT, Westlund KN: Immunocytochemical localization of dopamine-beta-hydroxylase in neurons of the human brain stem. Neuroscience. 1987, 23: 981-989. 10.1016/0306-4522(87)90173-4.View ArticlePubMedGoogle Scholar
  36. Oka K, Kijikawa K, Ohuchi T, Yoshida H, Imaizumi R: Distribution of dopamine-β-hydroxylase activity in subcellular fractions of adrenal medulla. Life Sci. 1967, 6: 461-465. 10.1016/0024-3205(67)90048-3.View ArticlePubMedGoogle Scholar
  37. Weinshilboum RM: Biochemical genetics of catecholamines in humans. Mayo Clin Proc. 1983, 58: 319-330.PubMedGoogle Scholar
  38. Craig SP, Buckle VJ, Lamouroux A, Mallet J, Craig IW: Localization of the human dopamine beta hydroxylase (DBH) gene to chromosome 9q34. Cytogenet Cell Genet. 1988, 48: 48-50.View ArticlePubMedGoogle Scholar
  39. Zabetian CP, Anderson GM, Buxbaum SG, Elston RC, Ichinose H, Nagatsu T, Kim KS, Kim CH, Malison RT, Gelernter J, Cubells JF: A quantitative-trait analysis of human plasma-dopamine beta-hydroxylase activity: Evidence for a major functional polymorphism at the DBH locus. Am J Hum Genet. 2001, 68: 515-522. 10.1086/318198.View ArticlePubMedPubMed CentralGoogle Scholar
  40. Köhnke MD, Zabetian CP, Anderson GM, Kolb W, Gaertner I, Buchkremer G, Vonthein R, Schick S, Lutz U, Köhnke AM, Cubells JF: A genotype-controlled analysis of plasma dopamine beta-hydroxylase in healthy and alcoholic subjects: evidence for alcohol-related differences in noradrenergic function. Biol Psychiatry. 2002, 52: 1151-1158. 10.1016/S0006-3223(02)01427-0.View ArticlePubMedGoogle Scholar
  41. Zabetian CP, Buxbaum SG, Elston RC, Köhnke MD, Anderson GM, Gelernter J, Cubells JF: The structure of linkage disequilibrium at the DBH locus strongly influences the magnitude of association between diallelic markers and plasma dopamine beta-hydroxylase activity. Am J Hum Genet. 2003, 72: 1389-1400. 10.1086/375499.View ArticlePubMedPubMed CentralGoogle Scholar
  42. Jönsson E, Sedvall G, Brené S, Gustavsson JP, Geijer T, Terenius L, Crocq M-A, Lannfelt L, Tylec A, Sokoloff P, Schwartz JC, Wiesel F-A: Dopamine-related genes and their relationships to monoamine metabolites in CSF. Biol Psychiatry. 1996, 40: 1032-1043. 10.1016/0006-3223(95)00581-1.View ArticlePubMedGoogle Scholar
  43. Jönsson EG, Norton N, Gustavsson JP, Oreland L, Owen MJ, Sedvall GC: A promoter polymorphism in the monoamine oxidase A gene and its relationships to monoamine metabolite concentrations in CSF of healthy volunteers. J Psychiatr Res. 2000, 34: 239-244. 10.1016/S0022-3956(00)00013-3.View ArticlePubMedGoogle Scholar
  44. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 1987, Washington DC: American Psychiatric Association, ThirdGoogle Scholar
  45. Sedvall G, Fyrö B, Gullberg B, Nybäck H, Wiesel F-A, Wode-Helgodt B: Relationships in healthy volunteers between concentrations of monoamine metabolites in cerebrospinal fluid and family history of psychiatric morbidity. Br J Psychiatry. 1980, 136: 366-374.View ArticlePubMedGoogle Scholar
  46. Swahn C-G, Sandgärde B, Wiesel F-A, Sedvall G: Simultaneous determination of the three major monoamine metabolites in brain tissue and body fluids by a mass fragmentographic method. Psychopharmacology. 1976, 48: 147-152.View ArticleGoogle Scholar
  47. Geijer T, Neiman J, Rydberg U, Gyllander A, Jönsson E, Sedvall G, Valverius P, Terenius L: Dopamine D2 receptor gene polymorphisms in Scandinavian chronic alcoholics. Eur Arch Psychiatry Clin Neurosci. 1994, 244: 26-32.View ArticlePubMedGoogle Scholar
  48. Jönsson EG, Abou Jamra R, Schumacher J, Flyckt L, Edman G, Forslund K, Mattila-Evenden M, Rylander G, Åsberg M, Bjerkenstedt L, Wiesel F-A, Propping P, Cichon S, Nöthen MM, Sedvall GC: No association between a putative functional promoter variant in the dopamine β-hydroxylase gene and schizophrenia. Psychiatr Genet. 2003, 13: 175-178. 10.1097/00041444-200309000-00007.View ArticlePubMedGoogle Scholar
  49. Jönsson EG, Goldman D, Spurlock G, Gustavsson JP, Nielsen DA, Linnoila M, Owen MJ, Sedvall GC: Tryptophan hydroxylase and catechol-O-methyltransferase gene polymorphisms. Relationships to monoamine metabolite concentrations in CSF of healthy volunteers. Eur Arch Psychiatry Clin Neurosci. 1997, 247: 297-302.View ArticlePubMedGoogle Scholar
  50. Cohen J: Statistical power analysis for the behavioral sciences. 1988, Hillsdale, New Jersey: Lawrence Erlbaum AssociatesGoogle Scholar
  51. Erdfelder E, Faul F, Buchner A: GPower: a general power analysis program. Behav Res Methods Instruments Comput. 1996, 28: 1-11.View ArticleGoogle Scholar
  52. Comings DE, MacMurray JP: Molecular heterosis: a review. Mol Genet Metab. 2000, 71: 19-31. 10.1006/mgme.2000.3015.View ArticlePubMedGoogle Scholar
  53. Adamson MD, Kennedy J, Petronis A, Dean M, Virkkunen M, Linnoila M, Goldman D: DRD4 dopamine receptor genotype and CSF monoamine metabolites in Finnish alcoholics and controls. Am J Med Genet. 1995, 60: 199-205.View ArticlePubMedGoogle Scholar
  54. Svensson TH: Brain noradrenaline and the mechanisms of action of antidepressant drugs. Acta Psychiatr Scand. 2000, Suppl., 402: 18-27.Google Scholar
  55. Blier P: Crosstalk between the norepinephrine and serotonin systems and its role in the antidepressant response. J Psychiatry Neurosci. 2001, 26: S3-S10.PubMedPubMed CentralGoogle Scholar
  56. Williams RB, Marchuk DA, Gadde KM, Barefoot JC, Grichnik K, Helms MJ, Kuhn CM, Lewis JG, Schanberg SM, Stafford-Smith M, Suarez EC, Clary GL, Svenson IK, Siegler IC: Serotonin-related gene polymorphisms and central nervous system serotonin function. Neuropsychopharmacology. 2003, 28: 533-541. 10.1038/sj.npp.1300054.View ArticlePubMedGoogle Scholar
  57. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-244X/4/4/prepub

Copyright

© Jönsson et al; licensee BioMed Central Ltd. 2004

This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

Advertisement